|
The Fourteenth Meeting of the
Parties decided
1. to
request each Party or regional economic integration organization to submit
available information to the Ozone Secretariat by 28 February 2003 and annual
updates thereafter the following information concerning inhaler treatments for
asthma and COPD that contain CFCs or that do not contain CFCs:
(a) CFC and non-CFC metered-dose inhalers and
dry-powder inhalers: sold or distributed within the Party, by active
ingredient, brand/manufacturer, and source (import or domestic production);
(b) CFC and non-CFC metered-dose inhalers and
dry-powder inhalers: produced within the Party for export to other Parties, by
active ingredient, brand/manufacturer, source and importing Party;
(c) non-CFC metered-dose inhalers and dry-powder
inhalers: date approved, authorized for marketing, and/or launched in the
territory of the Party;
2. to
request the Technology and Economic Assessment Panel to take into account
information submitted pursuant to paragraph 1 and other available information
in its annual assessment, and to request the Parties to pay due consideration
to this information when reviewing their national transition strategies.
(UNEP/OzL.Pro.14/9,
Decision XIV/5).
|